BR112017019287A2 - composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit - Google Patents

composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit

Info

Publication number
BR112017019287A2
BR112017019287A2 BR112017019287-0A BR112017019287A BR112017019287A2 BR 112017019287 A2 BR112017019287 A2 BR 112017019287A2 BR 112017019287 A BR112017019287 A BR 112017019287A BR 112017019287 A2 BR112017019287 A2 BR 112017019287A2
Authority
BR
Brazil
Prior art keywords
compound
formula
kit
preparing
pharmaceutically acceptable
Prior art date
Application number
BR112017019287-0A
Other languages
English (en)
Other versions
BR112017019287B1 (pt
Inventor
Duan Jian-Xin
Cao Yeyu
Cai Xiaohong
Jiao Hailong
Yuan Ma Jing
Matteucci Mark
Original Assignee
Obi Pharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Obi Pharma, Inc. filed Critical Obi Pharma, Inc.
Publication of BR112017019287A2 publication Critical patent/BR112017019287A2/pt
Publication of BR112017019287B1 publication Critical patent/BR112017019287B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2466—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit neste documento são fornecidos compostos da fórmula i: i onde as variáveis são aqui definidas, processos para sua preparação e métodos para tratar câncer, que compreendem a ministração de tais compostos.
BR112017019287-0A 2015-03-10 2016-03-09 Composto, e composição farmaceuticamente aceitável BR112017019287B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562131163P 2015-03-10 2015-03-10
US62/131,163 2015-03-10
USUS62/131163 2015-03-10
US201562255916P 2015-11-16 2015-11-16
USUS62/255916 2015-11-16
US62/255,916 2015-11-16
PCT/US2016/021581 WO2016145092A1 (en) 2015-03-10 2016-03-09 Dna alkylating agents

Publications (2)

Publication Number Publication Date
BR112017019287A2 true BR112017019287A2 (pt) 2018-05-02
BR112017019287B1 BR112017019287B1 (pt) 2024-01-02

Family

ID=56879139

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019287-0A BR112017019287B1 (pt) 2015-03-10 2016-03-09 Composto, e composição farmaceuticamente aceitável

Country Status (14)

Country Link
US (2) US10364261B2 (pt)
EP (2) EP3277380B1 (pt)
JP (1) JP6704421B2 (pt)
KR (4) KR102034618B1 (pt)
CN (1) CN107530556B (pt)
AU (1) AU2016229136B2 (pt)
BR (1) BR112017019287B1 (pt)
CA (1) CA2979251C (pt)
ES (2) ES2896960T3 (pt)
IL (1) IL254377B (pt)
MY (1) MY192888A (pt)
SG (2) SG11201707293VA (pt)
TW (1) TWI674258B (pt)
WO (1) WO2016145092A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5922791B2 (ja) 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
WO2017087428A1 (en) * 2015-11-16 2017-05-26 Threshold Pharmaceuticals, Inc. (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
WO2016011195A1 (en) 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
SG11201707293VA (en) 2015-03-10 2017-10-30 Ascenta Pharmaceuticals Ltd Dna alkylating agents
EP3277381A4 (en) 2015-04-02 2018-12-05 Obi Pharma, Inc. Nitrobenzyl derivatives of anti-cancer agents
WO2016210175A1 (en) 2015-06-24 2016-12-29 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
TW201919644A (zh) * 2017-09-29 2019-06-01 台灣浩鼎生技股份有限公司 治療血癌的方法
CN110693892A (zh) 2018-07-09 2020-01-17 深圳艾欣达伟医药科技有限公司 化合物用于制备预防、治疗或改善疼痛的药物的用途
EP3921295A4 (en) 2019-02-21 2022-05-04 OBI Pharma, Inc. PROCESS FOR THE PRODUCTION OF HIGHLY ANTIOSELECTIVE SECONDARY ALCOHOLS
JP2022533346A (ja) * 2019-05-13 2022-07-22 アセンタウィッツ ファーマシューティカルズ リミテッド フッ素含有化合物およびその抗癌医学的使用
WO2021000862A1 (zh) * 2019-07-01 2021-01-07 深圳艾欣达伟医药科技有限公司 Akr1c3抑制剂及医药用途
EP3995480A4 (en) * 2019-07-01 2023-10-25 Ascentawits Pharmaceuticals, Ltd. AKR1C3 INHIBITOR AND MEDICAL USE
CN112220742A (zh) * 2019-07-15 2021-01-15 深圳艾欣达伟医药科技有限公司 稳定的ast-3424注射液制剂及制备方法
UY38806A (es) 2019-08-01 2021-02-26 Novartis Ag Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos
WO2021068952A1 (zh) * 2019-10-12 2021-04-15 南京明德新药研发有限公司 靶向醛酮还原酶1c3的苯并二氢吡喃类化合物
CN112755001B (zh) 2019-11-01 2022-04-12 深圳艾欣达伟医药科技有限公司 口服给药的固体剂型药物
WO2021083310A1 (zh) 2019-11-01 2021-05-06 深圳艾欣达伟医药科技有限公司 作为非pgp底物的抗癌化合物
CN112904026A (zh) 2019-12-03 2021-06-04 深圳艾欣达伟医药科技有限公司 通过前列腺素含量来关联akr1c3酶表达水平及筛选给药用途
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途
CA3192258A1 (en) 2020-09-02 2022-03-10 Ascentawits Pharmaceuticals, Ltd. Akr1c3 detection method, and diagnostic kit for detecting akr1c3 and use thereof
WO2022057838A1 (zh) * 2020-09-18 2022-03-24 南京明德新药研发有限公司 异色满类化合物
KR20230148146A (ko) * 2021-02-26 2023-10-24 아센타위츠 파마슈티컬즈 리미티드 Akr1c3-활성화된 화합물의 용도
JP2024508546A (ja) 2021-03-05 2024-02-27 アセンタウィッツ ファーマシューティカルズ リミテッド プライマー－プローブ組成物、キット、および検出方法
CN115869325A (zh) 2021-09-26 2023-03-31 深圳艾欣达伟医药科技有限公司 化合物用于制备治疗kras突变癌症患者的药物的用途
WO2023077452A1 (zh) 2021-11-05 2023-05-11 深圳艾欣达伟医药科技有限公司 Akr1c3活化的dna烷化剂及其医药用途
CN116120365A (zh) * 2021-11-12 2023-05-16 深圳艾欣达伟医药科技有限公司 一种氘代化合物及其制备方法和应用
WO2023169462A1 (zh) * 2022-03-10 2023-09-14 深圳扬厉医药技术有限公司 异色满类化合物的晶型
WO2023174319A1 (zh) * 2022-03-15 2023-09-21 深圳艾欣达伟医药科技有限公司 治疗brca突变癌症患者的方法
WO2023226959A1 (zh) * 2022-05-23 2023-11-30 深圳艾欣达伟医药科技有限公司 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法
WO2024023659A1 (en) 2022-07-26 2024-02-01 Novartis Ag Pharmaceutical compositions of tricyclic akr1c3 dependent kars inhibitor and methods for making same
WO2024023641A1 (en) 2022-07-26 2024-02-01 Novartis Ag Methods of tricyclic akr1c3 dependent kars inhibitor dosing field of the invention
WO2024078392A1 (en) * 2022-10-09 2024-04-18 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Phosphoramidate compounds and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306727A (en) * 1993-04-30 1994-04-26 Research Corporation Technologies, Inc. Phosphoramidates useful as antitumor agents
US6482953B1 (en) 2001-12-03 2002-11-19 Eastman Kodak Company 2-benzyloxy-4-nitro-5-substituted-acylanilide compounds and method of using them
ZA200507752B (en) 2003-03-28 2007-01-31 Threshold Pharmaceuticals Inc Compositions and methods for treating cancer
US20040214798A1 (en) 2003-04-22 2004-10-28 Longqin Hu Nitroaryl phosphoramide compositions and methods for targeting and inhibiting undesirable cell growth or proliferation
DE102004020570A1 (de) 2004-04-27 2005-11-24 Bayer Healthcare Ag Substituierte Phenylaminopyrimidine
CA2587210A1 (en) 2004-11-22 2006-06-01 Threshold Pharmaceuticals, Inc. Tubulin binding anti cancer agents and prodrugs thereof
WO2007002931A2 (en) * 2005-06-29 2007-01-04 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
DE602006015861D1 (de) 2005-12-21 2010-09-09 Abbott Lab Antivirale verbindungen
WO2007098089A2 (en) 2006-02-17 2007-08-30 Novacea, Inc. Treatment of hyperproliferative diseases with methotrexate n-oxide and analogs
WO2008083101A1 (en) 2006-12-26 2008-07-10 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs for the treatment of cancer
WO2008151253A1 (en) 2007-06-04 2008-12-11 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of antineoplastic agents
WO2009018163A1 (en) 2007-07-27 2009-02-05 Threshold Pharmaceuticals, Inc. Hypoxia activated prodrugs of anthracyclines
WO2010044686A1 (en) 2008-10-17 2010-04-22 Auckland Uniservices Limited Akr1c3 as a biomarker, methods of selecting and treating patients based upon an akr1c3 profile and compounds for use therein
EP2350664B1 (en) 2008-10-21 2021-05-19 ImmunoGenesis, Inc. Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed
US20120322768A1 (en) * 2009-11-24 2012-12-20 Queen Mary & Westfield College Compounds, compositions and methods for treating protozoan infections
ES2877629T3 (es) * 2010-07-12 2021-11-17 Immunogenesis Inc Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
CN102924507A (zh) 2011-11-10 2013-02-13 安徽四维药业有限公司 一种抗肿瘤化合物及其制备方法与应用、药物组合物
US20150141530A1 (en) 2012-05-18 2015-05-21 University Of Louisville Research Foundation, Inc. Method and system for predicting recurrence and non-recurrence of melanoma using sentinel lymph node biomarkers
WO2017087428A1 (en) 2015-11-16 2017-05-26 Threshold Pharmaceuticals, Inc. (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
EP2958889B1 (en) 2013-02-25 2017-03-22 The Scripps Research Institute Neoseptins: small molecule adjuvants
JP2016538331A (ja) 2013-10-10 2016-12-08 メルク パテント ゲーエムベーハー Ｃα置換Ｎ−アルキル−グリシンエステル誘導体を介した１−アルキル−２−アミノ−イミダゾール−５−カルボン酸エステルの合成
SG11201707293VA (en) 2015-03-10 2017-10-30 Ascenta Pharmaceuticals Ltd Dna alkylating agents
EP3277381A4 (en) 2015-04-02 2018-12-05 Obi Pharma, Inc. Nitrobenzyl derivatives of anti-cancer agents
WO2016210175A1 (en) * 2015-06-24 2016-12-29 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents

Also Published As

Publication number Publication date
EP3277380A4 (en) 2018-08-01
SG11201707293VA (en) 2017-10-30
JP2018513876A (ja) 2018-05-31
IL254377B (en) 2021-08-31
KR20190072689A (ko) 2019-06-25
MY192888A (en) 2022-09-14
US20190225633A1 (en) 2019-07-25
EP3747508B1 (en) 2021-10-13
KR20190072688A (ko) 2019-06-25
CN107530556A (zh) 2018-01-02
US10364261B2 (en) 2019-07-30
KR102284031B1 (ko) 2021-07-30
EP3277380A1 (en) 2018-02-07
KR20210095231A (ko) 2021-07-30
SG10201913462XA (en) 2020-03-30
AU2016229136B2 (en) 2018-08-09
KR102034618B1 (ko) 2019-10-21
IL254377A0 (en) 2017-11-30
KR102398323B1 (ko) 2022-05-16
CA2979251A1 (en) 2016-09-15
ES2828026T3 (es) 2021-05-25
EP3277380B1 (en) 2020-09-16
US10766914B2 (en) 2020-09-08
KR20170128280A (ko) 2017-11-22
EP3747508A1 (en) 2020-12-09
BR112017019287B1 (pt) 2024-01-02
AU2016229136A1 (en) 2017-10-05
CN107530556B (zh) 2020-04-10
CA2979251C (en) 2021-03-23
US20180044360A1 (en) 2018-02-15
ES2896960T3 (es) 2022-02-28
JP6704421B2 (ja) 2020-06-03
KR102189066B1 (ko) 2020-12-09
WO2016145092A1 (en) 2016-09-15
TW201706262A (zh) 2017-02-16
TWI674258B (zh) 2019-10-11

Similar Documents

Publication Publication Date Title
BR112017019287A2 (pt) composto, composição farmaceuticamente aceitável, método de tratamento de câncer, processo para preparar o composto da fórmula i, método para tratar câncer, e kit
BR112017021167A2 (pt) composto, método de tratamento de câncer, e processo para preparar o composto de fórmula i
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
PH12020550901A1 (en) Macrocyclic compounds for treating disease
PH12018500981A1 (en) Treatment of osteoarthritis
CL2019001344A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de cerebro incluyendo el polimorfo cristalino del hexoxido tetraarsenico y el método para preparar el mismo.
GEP20207160B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
BR112016023558A2 (pt) compostos úteis como imunomoduladores
MY197440A (en) Heteroamatic compounds as btk inhibitors
DOP2017000278A (es) Piridinas sustituidas y método de uso
BR112017018092A2 (pt) composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio.
MX370628B (es) Composiciones y metodos para tratar las espinillas.
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer
NI201600163A (es) Derivados de diheterociclo enlazado a cicloalquilo
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
IL279208A (en) Therapeutic methods and compositions for the treatment of pancreatic cancer using 6, 8-bis(benzylsulfenyl)octanoic acid
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento
WO2017095950A3 (en) Compounds for treating proliferative diseases
BR112018075086A2 (pt) derivados de pirazolilaminobenzimidazol como inibidores de jak
EA201650085A1 (ru) Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида
BR112018073300A2 (pt) métodos para tratamento de doenças associadas com as células ilc3

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/03/2016, OBSERVADAS AS CONDICOES LEGAIS